Search
FDA Approves Qihan Biotech's First Universal Dual-Target CAR-T Cell Therapy for Clinical Trials
2025-08-14 /
Read about 0 minute
Author：小编
Qihan Biotech's pioneering universal CAR-T cell product, QT-019B, has secured approval from the Food and Drug Administration (FDA) for clinical trials in the United States. This groundbreaking therapy is designed to treat refractory systemic lupus erythematosus (SLE). By eliminating TCR expression, QT-019B minimizes the risk of graft-versus-host disease (GVHD). Additionally, it employs advanced multi-gene editing technology to ensure low immunogenicity, thereby reducing immune rejection reactions.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
